濮阳东方医院男科看阳痿(濮阳东方看男科病非常专业) (今日更新中)

HAVANA, Sept. 6 (Xinhua) -- Cuban medical authorities have launched the sales of the world's first therapeutic vaccine against lung cancer, local officials said on Tuesday.The CimaVax-EGF vaccine, as a result of a 25-year research into diseases related to tobacco smoking, has been developed by researchers and scientists at the Center of Molecular Immunology (CIM) in Havana.The active drug ingredient in the vaccine is based on "a protein we all have when cancer is uncontrolled." "The epidermal growth factor is related to all cell proliferation," said Gisela Gonzalez, head researcher of the project."The drug could turn the cancer into a manageable, chronic disease by generating antibodies against the proteins which triggered the uncontrolled cell proliferation," she said.The immunogenic vaccine is appropriate to patients with advanced lung cancer in stages of three and four, showing no positive response to other kinds of treatments such as chemotherapy and radiotherapy, the expert said."It is not possible to prevent the disease but this vaccine improves significantly the status of the critically ill patients," she added.She said the CimaVax-EGF has gone through clinical studies and trials in over 1,000 patients across the island and is currently distributed free of charge in all hospitals of the Caribbean island nation.Gonzalez also said researchers at the CIM planned to use the same principle of the CimaVax-EGF in treating other cancerous tumors such as prostate, uterus and breast cancers.Lung cancer is regarded as one of the world's most serious, common and deadly cancers and is most frequently found among tobacco smokers.According to the World Health Organization, the disease generally kills 5 million people a year, and the figure is expected to rise to as much as 8 million by 2030 unless smoking habits are changed.In Cuba, like many other developing countries across the world, smoking is seen as a status symbol. Lung cancer, killing about 20,000 people a year in the Caribbean country, is considered a serious threat to public health and the leading cause of death in 12 of the country's 15 provinces.

SYDNEY, July 1 (Xinhua) -- Breastfeeding mothers should limit their use of codeine-containing painkillers to four days as they can cause harm, an Australian doctor warned on Friday.The warning is being discussed at a meeting of anesthetists in Sydney."New mothers should limit their use of codeine-containing painkillers to no more than four days and, if they feel drowsy while taking this medication, cease its use and have their baby examined by a doctor for signs of drowsiness," Sydney's Royal North Shore Hospital anesthetist Dr. Gavin Pattullo said."This is because codeine needs to be metabolized by the liver into morphine to offer pain relief and this liver conversion process is very unpredictable," Pattullo said."Some patients' livers produce large amounts of morphine after taking codeine, causing drowsiness, while others fail to produce any morphine at all."Pattullo said for breastfeeding mothers, a large dose of morphine could make its way into the baby and result in the baby's death by overdose."While new mums shouldn't be unnecessarily alarmed, they need to be aware that codeine-containing painkillers in certain circumstances can cause harm," he said.Breastfeeding mothers are being advised to see a doctor if their baby gets sleepy while taking the painkillers.

New York, Sept. 23 (Xinhua) -- A Chinese scientist was presented a prestigious U.S. award on Friday for the discovery of artemisinin, a drug therapy for malaria that has saved millions of lives across the globe, especially in the developing world.Pharmacologist Tu Youyou, 81, became the first scientist on the Chinese mainland to win Lasker Award, known as "America's Nobels" for their knack of gaining future recognition by the Nobel committee.Tu, a scientist at the China Academy of Chinese Medical Sciences in Beijing, pioneered a new approach to malaria treatment that has benefited hundreds of millions of people and promises to benefit many times more. By applying modern techniques and rigor to a heritage provided by 5000 years of Chinese traditional practitioners, she has delivered its riches into the 21st century."Not often in the history of clinical medicine can we celebrate a discovery that has eased the pain and distress of hundreds of millions of people and saved the lives of countless numbers of people, particularly children, in over 100 countries," Lucy Shapiro, a member of the award jury and professor of Stanford University, said while describing Tu' s discovery.Shapiro said the discovery, chemical identification, and validation of artemisinin, a highly effective anti-malarial drug, is largely due to the "scientific insight, vision and dogged determination" of Professor Tu and her team. She thought Professor Tu's work has provided the world with arguably the most important pharmaceutical intervention in the last half century."The discovery of artemisinin is a gift to mankind from traditional Chinese medicine," Tu said while receiving the award. "Continuous exploration and development of traditional medicine will, without doubt, bring more medicines to the world."

BEIJING, Sept. 27 (Xinhuanet) -- Last-minute preparations for the launch of the Tiangong-1 spacecraft began at the Jiuquan Satellite Launch Center on Monday, meaning the vehicle can soon embark on a mission that will eventually have it dock with a spaceship, according to the center.That feat, if carried out successfully, will mark the completion of China's first rendezvous and docking mission.At the launch site on Monday afternoon, crews were putting in place pipes and cables that will be used to inject fuel into the rocket that will carry Tiangong-1 into outer space.Without complications from the weather or other causes, the Long March II-F rocket will lift off from the launch center on Thursday or Friday, taking the Tiangong-1 with it, according to the Xinhua News Agency.Despite the preparations, space experts said carrying out the plan still comes with many risks. They explained that the spacecraft and much of the other equipment being used is new and has not been tried on an actual mission."Tiangong-1 is a brand new spacecraft designed by China and is bigger and heavier than the Shenzhou spaceships China had developed as a means of transporting astronauts from the Earth to space," said Yang Hong, chief designer of Tiangong-1.In a vertical position, the Tiangong-1 looks like a cigar standing 10.4 meter tall, a height equal to that of a three-story building. It weighs 8.5 tons and has a maximum diameter of 3.35 meters, a dimension shared by its launch vehicle, he said.In comparison, the Shenzhou spaceship stands shorter, at nearly 9 meters, is slimmer, having a diameter of less than 3 meters, and weighs less.In another difference, the Tiangong-1 is composed of two modules rather than the three that had made up the Shenzhou spaceship. Of the Tiangong-1's two primary components, one is an experimental module that contains a place that astronauts can live and work in on future missions. It is also equipped with a docking port.The other chief component, a resource module, will provide the craft with power.Astronauts on Tiangong-1 will have 15 cubic meters of space to move in, "much more than they had in the Shenzhou spaceship", Yang said.Inside the spacecraft are two sleeping sections with adjustable lighting systems, exercise equipment, entertainment systems and visual communication devices, he said.Hou Xiangyang, who helped design Tiangong-1, said: "The sleeping section is big enough for a 1.8-meter-tall man to sleep in. An astronaut can adjust the light as he likes."In space, Tiangong-1 will fly in a horizontal position. A paint scheme inside will help the astronauts aboard maintain their sense of direction; the module's inner walls will be in two colors, one commonly associated with the sky and one with the ground."This will help astronauts avoid feeling as if they are standing upside down in the microgravity environment," he said.Yang said the Tiangong-1 spacecraft is expected to stay in orbit for two years and rendezvous and dock with three different spaceships. Beyond the Shenzhou VIII, ships named Shenzhou IX and Shenzhou X will embark on similar missions; at least one of the two is to be manned.Before astronauts climb on board Tiangong-1, the conditions inside its experimental module will be adjusted to ensure they can live in an environment that contains enough oxygen, moisture and heat to be safe.Tiangong-1 was originally scheduled to be launched into a low orbit around the Earth between Sept 27 and 30. The earlier days were removed as possible launch dates, though, after forecasters predicted a cold air mass would move into the area containing the Jiuquan Satellite Launch Center.To ensure the spacecraft and Long March II-F carrier rocket are ready for launch, a full ground simulation was conducted on Sunday afternoon.

来源：资阳报